Deals of the Week: Watson/Actavis, Pfizer/Nestle, Celgene/Epizyme
With Bayer reportedly preparing to strike a multi-billion-dollar deal, investors are reacting by driving up the price of two different potential targets.
You may also be interested in...
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.
“Our plan is to continue our dialogue with the FDA and see if we can address their concerns and get the accelerated approval done,” Onyx R&D chief Love told analysts. The company completed its application to treat patients with refractory and relapsed multiple myeloma in September based on results of a single-arm study, a design the agency may not be inclined to accept.
Onyx dropped its lawsuit against partner Bayer in exchange for an agreement that lets it share the financial rewards of the compound at the heart of the controvers, regorafenib, now in Phase III for oncology indications.